Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

NCT06017271 | Withdrawn

• 1 other identifier: XJTU1AF2023LSK-269
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.

Conditions

Pulmonary Embolism; Lung Cancer

Outcome Measures

Primary Outcomes (2)

• EAT volume

  volume of epicardial adipose tissue (EAT), Cm3

  May, 20, 2023

• EAT density

  density of epicardial adipose tissue (EAT) , Hounsfield Units (HU)

  May, 20, 2023

Study Arms (2)

PE group

The CTPA diagnosis suggest pulmonary embolism

Diagnostic Test: CTPA (computed tomography pulmonary angiography)

control group

The CTPA diagnosis did not suggest pulmonary embolism

Diagnostic Test: CTPA (computed tomography pulmonary angiography)

Interventions

CTPA (computed tomography pulmonary angiography) DIAGNOSTIC_TEST

The CTPA diagnosis suggest or did not suggest pulmonary embolism.

PE group; control group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study was conducted on patients with a confirmed diagnosis of Lung Cancer who were admitted to the First Affiliated Hospital of Xi'an Jiaotong University from 1 January 2012 to 31 December 2021. Patients who did not meet any of the inclusion criteria or met any of the exclusion criteria were excluded. The subjects were divided into PE group and control group according to the results of CTPA examination, and the patients in the two groups were matched by gender and age 1:1 tendency score.

You may qualify if:

• The pathological diagnosis was lung cancer
• Pulmonary artery was evaluated by CTA during hospitalization.

You may not qualify if:

• Patients with incomplete clinical data
• Patients with no follow-up data
• Patients with a history of PE before diagnosis of lung cancer

Sponsors & Collaborators

• First Affiliated Hospital Xi'an Jiaotong University: lead

Study Sites (1)

First Affiliated Hospital of Xian Jiaotong University

Xi'an, Shaanxi, 710061, China

Location

MeSH Terms

Conditions

Pulmonary Embolism; Lung Neoplasms

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Embolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms

Study Officials

• Yang Yan

  First Affiliated Hospital Xi'an Jiaotong University

  STUDY DIRECTOR

• Haichen Wang

  First Affiliated Hospital Xi'an Jiaotong University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2023
• First Posted: August 30, 2023
• Study Start: May 1, 2024
• Primary Completion: July 15, 2024
• Study Completion: July 19, 2024
• Last Updated: July 22, 2024

Record last verified: 2024-07

Locations

CN (1)